Diaxonhit Share Price Euronext Paris
Stocks
FR0004054427
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 205M 240M 192M 176M 330M 22.94B 335M 2.27B 885M 11.52B 900M 881M 38.12B | P/E 2026 * |
18.1x | P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 173M 202M 162M 149M 279M 19.37B 282M 1.92B 747M 9.73B 760M 744M 32.18B | EV / Sales 2026 * |
0.99x | EV / Sales 2027 * | - |
| Free-Float |
98.24% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -1.83% |
| Manager | Title | Age | Since |
|---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | 58 | 12/06/2023 |
Olivier Bosc
DFI | Director of Finance/CFO | - | 09/10/2023 |
Maarten Penning
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 31/12/2018 | |
Michel Picot
BRD | Director/Board Member | 73 | 26/06/2019 |
| Director/Board Member | 69 | 14/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.83% | -.--% | - | - | 240M | |
| +1.09% | +5.26% | +4.44% | +26.03% | 51.22B | |
| -1.48% | +2.16% | +470.50% | +596.75% | 45.38B | |
| +2.03% | +8.25% | +19.80% | +91.79% | 41.97B | |
| +1.11% | +9.23% | +39.44% | +20.59% | 42.15B | |
| -0.93% | -4.80% | +17.39% | +46.60% | 31.95B | |
| +0.57% | +2.85% | - | - | 16.73B | |
| +1.71% | +7.96% | +37.76% | +153.89% | 17.1B | |
| +0.03% | +3.41% | +7.12% | +35.49% | 14.76B | |
| +1.67% | +5.37% | +90.95% | +46.88% | 13.91B | |
| Average | +0.38% | +3.19% | +85.93% | +127.25% | 30.58B | |
| Weighted average by Cap. | +0.54% | +3.13% | +103.10% | +148.71% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 176M 205M 165M 151M 283M 19.65B 286M 1.94B 758M 9.87B 771M 754M 32.65B | - |
| Net income | 11.6M 13.54M 10.85M 9.94M 18.65M 1.3B 18.89M 128M 50.01M 651M 50.85M 49.74M 2.15B | - |
| Net Debt | -32M -37.36M -29.94M -27.41M -51.44M -3.57B -52.12M -354M -138M -1.8B -140M -137M -5.94B | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
